1-888-YUNG-NOW
888-986-4669

endothelial dysfunction

Erectile Dysfunction: More Than Sexual Dysfunction

No doubt about it, erectile dysfunction is a common problem in men, especially those older than 45 years. For all the advertising regarding Viagra, Cialis, and similar drugs, there is no mention that it may indicate serious vascular disease. This symptom requires consideration of more serious problems.

When faced with this problem, I always like to do a workup to determine the cause. In many patients, drugs such as beta blockers, diuretics, and antidepressants may interfere with sexual function. One must be sure the erectile dysfunction is not due to vascular endothelial disease, especially of small vessels (arteriosclerosis). Erection depends on the integrity of the vascular system, especially the small vessels.

Research upholds this association and men with E.D. should be considered to have a 10-year cardiovascular event risk equal to men with Coronary Artery Disease or Diabetes or greater than 2% per year according to Framingham Chart of risk. I like to do a workup of cardiovascular risk factors in all patients. There are 17 distinct risk factors for myocardial infarction.

Sometimes in the younger patients, low testosterone, high estrogen and low DHEA can cause ED without strong evidence of CV disease. In younger patients who have sexual dysfunction, I also like to investigate whether having metal intoxication is playing a role.

After treatment of the endothelial dysfunction (arteriosclerosis) if present, a cost-effective and non-toxic treatment for E.D. is Pycnogenol (French maritime pine bark extract) and the amino acid arginine. The combination affects endothelial dysfunction and underlying disease of many E.D. cases. It causes an increase in Nitrous Oxide also, which increases blood flow by vasodilatation. Good blood flow is needed to develop and maintain an erection.

Tagged , , , , , , , , , , , , ,

New Knowledge About an Old Drug: Metformin

Metformin has a long history, beginning as a botanical compound several hundred years ago. It came on the scene as a new drug to treat Type II Diabetes in 1994 and became widely prescribed. Its benefit was soon recognized to include reduced mortality compared to other diabetic drugs; oral agents and insulin. Its ability to help in weight loss is widely known and it has demonstrated benefits in protecting against heart disease.

The focus on its anti-cancer benefits are now being recognized. Diabetics have a huge incidence of a broad range of cancers. Reduction of blood sugar and prevention of severe weight gain can result in closing many of the pathways that lead to cancer. Metformin apparently can accomplish these effects. It mimics the effects of severe calorie restrictions.

In 2005, it was noted from large population-based controls that taking Metformin for diabetics was a strong preventive for the high risk of developing cancer. This seemed to be especially true for preventing breast and endometrial cancer. It is also known to have positive effects in prostate, colon, and lung cancer.

Additional research suggests that Metformin may enhance the effects of radiation therapy in eradicating lung and other cancers.

The wealth of evidence of Metformin’s anti-cancer activity is now expanding to include not only those with diabetes or pre-diabetic conditions, but also people apparently otherwise healthy. It should be given serious consideration for inclusion in any cancer prevention program.

Metformin enhances insulin productivity and thereby prevents endothelial dysfunction and the resulting vascular disease.

I did not try to elaborate on the various pathways that Metformin influences, but most of them are fundamental to all cancers. It is reasonable to expect more research showing Metformin’s effect on a very wide range of tumors. This is a powerful anti-aging drug, yet a very safe one.

Tagged , , ,
Rss Feed Tweeter button Facebook button Myspace button Linkedin button
Top